AIM ImmunoTech Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $88,000 | $170,000 | $202,000 | $141,000 | $135,000 |
| Operating income | -$11.7M | -$19.8M | -$31.9M | -$19.9M | -$18.8M |
| Cash from operations | -$11.0M | -$14.9M | -$21.3M | -$16.1M | -$14.0M |
| Capital expenditure | — | $18,000 | — | $86,000 | $41,000 |
| Free cash flow | — | -$14.9M | — | -$16.2M | -$14.0M |
| Impairments | $1.1M | $48,000 | — | — | $1.8M |
| Total assets | $5.8M | $8.6M | $19.4M | $40.5M | $57.7M |
| Total liabilities | $15.6M | $9.9M | $9.1M | $2.0M | — |
| Total debt | $5.3M | $2.8M | — | — | — |
Shares outstanding 14.6M · Free float 75.9%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.